Clinical utility of lipoprotein(a) and the ApoB/ApoA-I ratio in the risk assessment of acute coronary syndrome: from single biomarkers to integrated risk stratification.
- DOI
- 10.3389/fcvm.2026.1937328
- Published
- 2026
- Container
- Frontiers in cardiovascular medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fcvm.2026.1937328,
title = {Clinical utility of lipoprotein(a) and the ApoB/ApoA-I ratio in the risk assessment of acute coronary syndrome: from single biomarkers to integrated risk stratification.},
author = {Lu Z and Li P and Li R and Guo X and Li S and Wang J},
year = {2026},
journal = {Frontiers in cardiovascular medicine},
doi = {10.3389/fcvm.2026.1937328},
url = {https://doi.org/10.3389/fcvm.2026.1937328}
}RIS
TY - JOUR TI - Clinical utility of lipoprotein(a) and the ApoB/ApoA-I ratio in the risk assessment of acute coronary syndrome: from single biomarkers to integrated risk stratification. AU - Lu Z AU - Li P AU - Li R AU - Guo X AU - Li S AU - Wang J PY - 2026 JO - Frontiers in cardiovascular medicine DO - 10.3389/fcvm.2026.1937328 UR - https://doi.org/10.3389/fcvm.2026.1937328 ER -
APA
Z, L., P, L., R, L., X, G., S, L., & J, W. (2026). Clinical utility of lipoprotein(a) and the ApoB/ApoA-I ratio in the risk assessment of acute coronary syndrome: from single biomarkers to integrated risk stratification.. Frontiers in cardiovascular medicine. https://doi.org/10.3389/fcvm.2026.1937328
Source records
- pubmed · retrieved 2026-09-26T18:39:02.934Z
- europe-pmc · retrieved 2026-09-26T18:39:02.946Z
- doaj · retrieved 2026-09-26T18:39:02.945Z